The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma

B. S. Hoppe, Craig Moskowitz, Z. Zhang, J. C. Maragulia, R. D. Rice, A. S. Reiner, P. A. Hamlin, A. D. Zelenetz, J. Yahalom

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

We examined the role of fluorodeoxyglucose-positron emission tomography (FDG-PET) and the addition of involved field radiotherapy (IFRT) as potential modifiers of salvage therapy. From January 2000 to June 2007, 83 patients with chemosensitive relapsed or primary refractory diffuse large B-cell lymphoma (DLBCL) underwent FDG-PET scans following second-line chemotherapy before high-dose therapy with autologous stem cell rescue (HDT/ASCR). We evaluated the prognostic value of having a negative FDG-PET scan before HDT/ASCR and whether IFRT improved the outcomes. Median follow-up was 45 months, and the 3-year PFS, disease-specific survival (DSS) and OS were 72, 80 and 78%, respectively. Multivariate analysis revealed that a positive FDG-PET scan had worse PFS (hazard ratio = (HR) 3.4; P = 0.014), DSS (HR = 7.7; P = 0.001) and OS (HR = 5.4; P = 0.001), and that patients not receiving IFRT had worse PFS (HR = 2.7; P = 0.03) and DSS (HR = 2.8, P = 0.059). Patients who received IFRT had better local control with fewer relapses within prior involved sites compared with those that did not receive IFRT (P = 0.006). These outcomes confirm the important prognostic value of FDG-PET scans before undergoing HDT/ASCR. It also suggests that the role of IFRT should be evaluated further.

Original languageEnglish (US)
Pages (from-to)941-948
Number of pages8
JournalBone Marrow Transplantation
Volume43
Issue number12
DOIs
StatePublished - Jan 13 2009
Externally publishedYes

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Positron-Emission Tomography
Radiotherapy
Stem Cells
Survival
Salvage Therapy
Therapeutics
Multivariate Analysis
Recurrence
Drug Therapy

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma. / Hoppe, B. S.; Moskowitz, Craig; Zhang, Z.; Maragulia, J. C.; Rice, R. D.; Reiner, A. S.; Hamlin, P. A.; Zelenetz, A. D.; Yahalom, J.

In: Bone Marrow Transplantation, Vol. 43, No. 12, 13.01.2009, p. 941-948.

Research output: Contribution to journalArticle

Hoppe, BS, Moskowitz, C, Zhang, Z, Maragulia, JC, Rice, RD, Reiner, AS, Hamlin, PA, Zelenetz, AD & Yahalom, J 2009, 'The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma', Bone Marrow Transplantation, vol. 43, no. 12, pp. 941-948. https://doi.org/10.1038/bmt.2008.408
Hoppe, B. S. ; Moskowitz, Craig ; Zhang, Z. ; Maragulia, J. C. ; Rice, R. D. ; Reiner, A. S. ; Hamlin, P. A. ; Zelenetz, A. D. ; Yahalom, J. / The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma. In: Bone Marrow Transplantation. 2009 ; Vol. 43, No. 12. pp. 941-948.
@article{96a1cb0fc23742a6ba0690380b90f445,
title = "The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma",
abstract = "We examined the role of fluorodeoxyglucose-positron emission tomography (FDG-PET) and the addition of involved field radiotherapy (IFRT) as potential modifiers of salvage therapy. From January 2000 to June 2007, 83 patients with chemosensitive relapsed or primary refractory diffuse large B-cell lymphoma (DLBCL) underwent FDG-PET scans following second-line chemotherapy before high-dose therapy with autologous stem cell rescue (HDT/ASCR). We evaluated the prognostic value of having a negative FDG-PET scan before HDT/ASCR and whether IFRT improved the outcomes. Median follow-up was 45 months, and the 3-year PFS, disease-specific survival (DSS) and OS were 72, 80 and 78{\%}, respectively. Multivariate analysis revealed that a positive FDG-PET scan had worse PFS (hazard ratio = (HR) 3.4; P = 0.014), DSS (HR = 7.7; P = 0.001) and OS (HR = 5.4; P = 0.001), and that patients not receiving IFRT had worse PFS (HR = 2.7; P = 0.03) and DSS (HR = 2.8, P = 0.059). Patients who received IFRT had better local control with fewer relapses within prior involved sites compared with those that did not receive IFRT (P = 0.006). These outcomes confirm the important prognostic value of FDG-PET scans before undergoing HDT/ASCR. It also suggests that the role of IFRT should be evaluated further.",
author = "Hoppe, {B. S.} and Craig Moskowitz and Z. Zhang and Maragulia, {J. C.} and Rice, {R. D.} and Reiner, {A. S.} and Hamlin, {P. A.} and Zelenetz, {A. D.} and J. Yahalom",
year = "2009",
month = "1",
day = "13",
doi = "10.1038/bmt.2008.408",
language = "English (US)",
volume = "43",
pages = "941--948",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma

AU - Hoppe, B. S.

AU - Moskowitz, Craig

AU - Zhang, Z.

AU - Maragulia, J. C.

AU - Rice, R. D.

AU - Reiner, A. S.

AU - Hamlin, P. A.

AU - Zelenetz, A. D.

AU - Yahalom, J.

PY - 2009/1/13

Y1 - 2009/1/13

N2 - We examined the role of fluorodeoxyglucose-positron emission tomography (FDG-PET) and the addition of involved field radiotherapy (IFRT) as potential modifiers of salvage therapy. From January 2000 to June 2007, 83 patients with chemosensitive relapsed or primary refractory diffuse large B-cell lymphoma (DLBCL) underwent FDG-PET scans following second-line chemotherapy before high-dose therapy with autologous stem cell rescue (HDT/ASCR). We evaluated the prognostic value of having a negative FDG-PET scan before HDT/ASCR and whether IFRT improved the outcomes. Median follow-up was 45 months, and the 3-year PFS, disease-specific survival (DSS) and OS were 72, 80 and 78%, respectively. Multivariate analysis revealed that a positive FDG-PET scan had worse PFS (hazard ratio = (HR) 3.4; P = 0.014), DSS (HR = 7.7; P = 0.001) and OS (HR = 5.4; P = 0.001), and that patients not receiving IFRT had worse PFS (HR = 2.7; P = 0.03) and DSS (HR = 2.8, P = 0.059). Patients who received IFRT had better local control with fewer relapses within prior involved sites compared with those that did not receive IFRT (P = 0.006). These outcomes confirm the important prognostic value of FDG-PET scans before undergoing HDT/ASCR. It also suggests that the role of IFRT should be evaluated further.

AB - We examined the role of fluorodeoxyglucose-positron emission tomography (FDG-PET) and the addition of involved field radiotherapy (IFRT) as potential modifiers of salvage therapy. From January 2000 to June 2007, 83 patients with chemosensitive relapsed or primary refractory diffuse large B-cell lymphoma (DLBCL) underwent FDG-PET scans following second-line chemotherapy before high-dose therapy with autologous stem cell rescue (HDT/ASCR). We evaluated the prognostic value of having a negative FDG-PET scan before HDT/ASCR and whether IFRT improved the outcomes. Median follow-up was 45 months, and the 3-year PFS, disease-specific survival (DSS) and OS were 72, 80 and 78%, respectively. Multivariate analysis revealed that a positive FDG-PET scan had worse PFS (hazard ratio = (HR) 3.4; P = 0.014), DSS (HR = 7.7; P = 0.001) and OS (HR = 5.4; P = 0.001), and that patients not receiving IFRT had worse PFS (HR = 2.7; P = 0.03) and DSS (HR = 2.8, P = 0.059). Patients who received IFRT had better local control with fewer relapses within prior involved sites compared with those that did not receive IFRT (P = 0.006). These outcomes confirm the important prognostic value of FDG-PET scans before undergoing HDT/ASCR. It also suggests that the role of IFRT should be evaluated further.

UR - http://www.scopus.com/inward/record.url?scp=67649884048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649884048&partnerID=8YFLogxK

U2 - 10.1038/bmt.2008.408

DO - 10.1038/bmt.2008.408

M3 - Article

C2 - 19139730

AN - SCOPUS:67649884048

VL - 43

SP - 941

EP - 948

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 12

ER -